135 related articles for article (PubMed ID: 33974430)
1. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
3. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
4. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
5. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
Liu S; Qiao W; Sun Q; Luo Y
J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
[TBL] [Abstract][Full Text] [Related]
6. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Inhibition Reveals Distinctive Properties for Human and
Shaikhqasem A; Dickmanns A; Neumann P; Ficner R
J Med Chem; 2020 Jul; 63(14):7545-7558. PubMed ID: 32585100
[TBL] [Abstract][Full Text] [Related]
8. Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Sui M; Xiong M; Li Y; Zhou Q; Shen X; Jia D; Gou M; Sun Q
Int J Nanomedicine; 2021; 16():2833-2847. PubMed ID: 33883894
[TBL] [Abstract][Full Text] [Related]
9. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
Sun Q; Carrasco YP; Hu Y; Guo X; Mirzaei H; Macmillan J; Chook YM
Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1303-8. PubMed ID: 23297231
[TBL] [Abstract][Full Text] [Related]
10. Correlation of CRM1-NES affinity with nuclear export activity.
Fu SC; Fung HYJ; Cağatay T; Baumhardt J; Chook YM
Mol Biol Cell; 2018 Aug; 29(17):2037-2044. PubMed ID: 29927350
[TBL] [Abstract][Full Text] [Related]
11. A 2.1-Å-resolution crystal structure of unliganded CRM1 reveals the mechanism of autoinhibition.
Saito N; Matsuura Y
J Mol Biol; 2013 Jan; 425(2):350-64. PubMed ID: 23164569
[TBL] [Abstract][Full Text] [Related]
12. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1.
Koyama M; Matsuura Y
EMBO J; 2010 Jun; 29(12):2002-13. PubMed ID: 20485264
[TBL] [Abstract][Full Text] [Related]
13. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
14. Electrostatic interactions involving the extreme C terminus of nuclear export factor CRM1 modulate its affinity for cargo.
Fox AM; Ciziene D; McLaughlin SH; Stewart M
J Biol Chem; 2011 Aug; 286(33):29325-29335. PubMed ID: 21708948
[TBL] [Abstract][Full Text] [Related]
15. Engineering chromosome region maintenance 1 fragments that bind to nuclear export signals.
Lei Y; An Q; Zhang Y; Luo P; Luo Y; Shen X; Jia D; Sun Q
Protein Sci; 2020 Jun; 29(6):1366-1372. PubMed ID: 31495993
[TBL] [Abstract][Full Text] [Related]
16. Novel Mechanistic Observations and NES-Binding Groove Features Revealed by the CRM1 Inhibitors Plumbagin and Oridonin.
Lei Y; Li Y; Tan Y; Qian Z; Zhou Q; Jia D; Sun Q
J Nat Prod; 2021 May; 84(5):1478-1488. PubMed ID: 33890470
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of nuclear export signal orientation in binding to exportin CRM1.
Fung HY; Fu SC; Brautigam CA; Chook YM
Elife; 2015 Sep; 4():. PubMed ID: 26349033
[TBL] [Abstract][Full Text] [Related]
18. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
19. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
20. Searching for Novel Noncovalent Nuclear Export Inhibitors through a Drug Repurposing Approach.
Huang W; Wang JX; Shen X; Lei Y; Chen X; Jia D; Zhang X; Sun Q
J Med Chem; 2023 Jan; 66(2):1574-1582. PubMed ID: 36622814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
